Effect of renal impairment on the pharmacokinetics of exenatide
Open Access
- 10 April 2007
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (3), 317-327
- https://doi.org/10.1111/j.1365-2125.2007.02890.x
Abstract
To evaluate the pharmacokinetics (PK), safety and tolerability of a single exenatide dose in patients with renal impairment (RI). Exenatide (5 or 10 µg) was injected subcutaneously in 31 subjects (one with Type 2 diabetes) stratified by renal function [Cockcroft–Gault creatinine clearance (CrCL), number of subjects]: normal (>80 ml min−1, n = 8), mild RI (51–80 ml min−1, n = 8), moderate RI (31–50 ml min−1, n = 7) or end-stage renal disease (ESRD) requiring haemodialysis (n = 8). PK data were combined with four previous single-dose studies in patients with Type 2 diabetes to explore the relationship of exenatide clearance (CLp/F) and CrCL. Mean half-life for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively. After combining data from multiple studies, least squares geometric means for CLp/F in subjects with normal renal function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 l h−1, respectively. Exenatide was generally well tolerated in the mild and moderate RI groups, but not in subjects with ESRD due to nausea and vomiting. Simulations of exenatide plasma concentrations also suggest patients with ESRD should have a propensity for poor tolerability at the lowest available therapeutic dosage (5 µg q.d.). Since tolerability and PK changes were considered clinically acceptable in patients with mild to moderate RI, it would be appropriate to administer exenatide to these patients without dosage adjustment. However, poor tolerability and significant changes in PK make the currently available therapeutic doses (5 and 10 µg) unsuitable in severe RI or ESRD.This publication has 18 references indexed in Scilit:
- A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)Clinical Therapeutics, 2005
- Glucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic PotentialBasic & Clinical Pharmacology & Toxicology, 2004
- New Insights into the Regulation of Glucagon Secretion by Glucagon-like Peptide-1Hormone and Metabolic Research, 2004
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2003
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1Drug Development Research, 2001
- Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCTDiabetes Research and Clinical Practice, 1998
- Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the ReceptorDiabetes, 1993
- Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptorDiabetes, 1993